Together, these findings suggest that LDHC silencing reduces the cancer cell viability of basal-like breast cancer cells in part through the downregulation of STAT3 signaling, whereas in HCC-1954 cells, the activation of STAT3 (through unknown mechanisms) negates this biological process, highlighting the cell line-dependent effects of LDHC silencing. The gene discussed is STAT3; the disease is hepatocellular carcinoma.